An interventional study of Myo-inositol 2 g + Folic acid 200 µg and Folic acid 200 µg in Gestational Diabetes Mellitus (GDM), sponsored by Medical University of Vienna. Recruiting at 2 sites in Austria. Open to female participants aged 18 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-07-06.
Sponsored by Medical University of Vienna · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Diabetes, Gestational with a site in Austria — 4 open to participants now, 5 under way, none of them phase 3. Diabetes, Gestational · Austria.
Among the 11 studies in Diabetes, Gestational with a site in Austria, this one is the only one that started in 2026, is one of 5 with no phase, and was the 9th registered.
878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.
Browse Diabetes, Gestational studies →4 of the 11 studies in Diabetes, Gestational with a site in Austria are open now. Recruiting first, the newest first:
Medical University of Graz · Sites in Austria
Ages 18+ · Women only
Istituto di Neuroscienze Consiglio Nazionale delle Ricerche · Sites in Austria, Italy
Ages 35+ · Women only
Medical University of Graz · Sites in Austria
Ages 18–50 · Women only · Healthy volunteers
A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →
Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.
This study: 18 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 40 is below the median of 110 across 563 interventional studies indexed under Diabetes, Gestational.
Median enrollment 67 across the 5 interventional studies, 275 across the 6 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 11 has an industry lead sponsor. The 3 most frequent:
Medical University of Vienna is the lead sponsor of 1,111 studies on the registry; 186 are open to participants now.
Medical University of Vienna has 8 studies filed under Diabetes, Gestational — fewer than ten, so there is no comparison to draw.
1 of the studies in Diabetes, Gestational with a site in Austria that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07685015Medical University of ViennaThe Impact of Myo-Inositol on Glycemic Control and Oxidative Stress in Gestational Diabetes Mellitus | 2027-04-01 |
Add it to your calendar (.ics) → With an account.
Among the 11 studies in Diabetes, Gestational with a site in Austria, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this clinical study is to investigate the potential effects of myo-inositol supplementation on changes in glycemic control parameters, oxidative stress, inflammatory biomarkers, psychometric markers, and body composition in participants with gestational diabetes mellitus (GDM).
The study duration is 3 to 3.5 months, depending on the time of GDM diagnosis. Before the active phase begins, there is a 10-day observation period during which participants' blood glucose levels are monitored using a continuous glucose monitoring device. In the subsequent 12-14-week study phase, participants will receive a supplement based on random group assignment. They will be allocated either to an intervention group (myo-inositol + folic acid) or a control group (folic acid). Both supplements will be taken until delivery.
The intervention group supplement contains 4 g myo-inositol and 400 μg folic acid (BIOGENA GmbH, Salzburg) and is to be taken twice daily with water - three capsules per meal. The control group supplement contains only 400 μg folic acid (BIOGENA GmbH, Salzburg) and is also taken twice daily, one capsule per meal. As this is a pilot study, both participants and study personnel will be aware of group assignments.
Blood glucose measurements will be repeated mid-study (around the 33rd week of pregnancy) and at the end (37th week of pregnancy) using glucose sensors. To improve the evaluation of glucose measurements, participants will keep dietary logs during these periods.
Three study visits are planned, during which the following assessments will be conducted. To determine the primary outcome, "time in range (TIR)" (time spent within the target glucose range), three glucose sensor measurements will be performed. At each visit, blood samples will be taken to analyze glycemic control parameters (hemoglobin A1c (HbA1c), fasting glucose, fasting insulin, Homeostasis Model Assessment (HOMA-IR), insulin dosage), oxidative stress markers (total antioxidant capacity, malondialdehyde levels), and inflammatory markers (interleukin-6 (IL-6), C-reactive protein (CRP)). Anthropometric measurements (weight gain, blood pressure, pulse) and body composition (Bioelectrical Impedance Analysis) will also be performed.
Additionally, maternal and fetal birth outcomes will be recorded, including cesarean section rates, fetal gestational weight, preterm birth rates, and neonatal hypoglycemia occurrence. To assess participants' well-being and physical activity, questionnaires will be distributed at the beginning and end of the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Women who maintain their blood glucose levels within the normal range through nutritional therapy and receive the investigational supplement myo-inositol plus folic acid.
Dietary Supplement: Myo-inositol 2 g + Folic acid 200 µg · Behavioral: Nutrition therapy
Women who are already receiving insulin therapy to maintain their blood glucose levels within the normal range and receive the investigational supplement myo-inositol plus folic acid.
Dietary Supplement: Myo-inositol 2 g + Folic acid 200 µg · Drug: Insulin therapy
Women who maintain their blood glucose levels within the normal range through nutritional therapy and receive the supplement folic acid.
Dietary Supplement: Folic acid 200 µg · Behavioral: Nutrition therapy
Women who are already receiving insulin therapy to maintain their blood glucose levels within the normal range and receive the supplement folic acid.
Dietary Supplement: Folic acid 200 µg · Drug: Insulin therapy
Drug page: InositolStudies of InositolInositol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
This dietary supplement contains 2 g of myo-inositol and 200 µg folic acid per capsule. It should be taken twice a day (à 3 capsules) with fluid intake and a meal.
This dietary supplement contains 200 μg of folic acid per capsule and should also be taken twice a day (à 1 capsule) with adequate fluid intake and a main meal.
Women with GDM who maintain their blood glucose levels with insulin therapy.
Women with GDM who maintain their blood sugar levels with nutritional therapy.
Time in Range
Time in Range \[%\] measured with continous glucose monitoring
Time frame: 10 days at baseline (24.-28. gestational week), 10 days into gestational week 33, 10 days into gestational week 36/37
Fasting glucose
fasting glucose \[mg/dl\] concentration
Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week
Fasting insulin
fasting insulin \[μIU/mL\] concentration
Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week
HOMA-IR
HOMA-IR calculated as fasting insulin level (micro-units per milliliter) multiplied by the fasting blood glucose level (milligrams per deciliter), dividing the result by 405
Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week
HbA1c
HbA1c \[%\] concentration
Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week
Insulin doses
insulin units \[IU\]
Time frame: from day 1 until delivery
Pre Pregnancy BMI
weight \[kg\]/height \[m\]\^2
Time frame: before pregnancy
Height in meters
height \[m\]
Time frame: at baseline
Weight in kilograms
weight \[kg\]
Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week
Blood Pressure
blood pressure \[mmHg\]
Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week
C-Section (maternal and fetal outcomes)
C-Section yes or no
Time frame: at delivery
Hypoglycemia of the child (maternal and fetal outcomes)
glucose values of the child \[mg/dl\]
Time frame: at delivery
Preterm birth (maternal and fetal outcomes)
delivery before 37. gestational week yes or no
Time frame: at delivery
Gestational weight of the child (maternal and fetal outcomes)
gestational weight of the child \[kg\]
Time frame: at delivery
Oxidative stress parameter
total antioxidative capacity \[µmol/l\]
Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week
Oxidative stress parameter
Malondialdehy status \[µmol/l\]
Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week
Inflammatory parameter
C-reactive protein \[mg/dl\]
Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week
Inflammatory parameter
interleucin-6 \[pg/ml\]
Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week
Psychometric parameter
Questionnaire: Pregnancy-related Anxiety score * minimum score: 10 * maximum score: 50
Time frame: 24.-28. gestational week, 37. gestational week
Psychometric parameter
Questionnaire: Postnatal-Depression score * total possible score: 0-30 * higher scores: more depressive symptoms
Time frame: 24.-28. gestational week, 37. gestational week
Psychometric parameter
Questionnaire: Perceived Stress score * minimum raw score: 20 * maximum raw score: 80
Time frame: 24.-28. gestational week, 37. gestational week
Physical Activity parameter
Questionnaire: Physical Activity score \[MET\] \- average daily energy expenditure by calculating the metabolic equivalents (METs) for each activity
Time frame: 24.-28. gestational week, 37. gestational week
Nutritional log
Food diary for 10 days
Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week
Bioelectrical Impedance Analysis (BIA)
fat mass \[kg\]
Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week
Bioelectrical Impedance Analysis (BIA)
total body water \[%\]
Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week
Bioelectrical Impedance Analysis (BIA)
muscle mass \[kg\]
Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week
Bioelectrical Impedance Analysis (BIA)
fat free mass \[%\]
Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week
Bioelectrical Impedance Analysis (BIA)
body cell mass \[%\]
Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week
Bioelectrical Impedance Analysis (BIA)
extracellular mass \[%\]
Time frame: 24.-28. gestational week, 33. gestational week, 37. gestational week
Plan to share: No
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Apr 2027, 12 months after the start.
Of 306 non-industry interventional studies with no phase under Diabetes, Gestational, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 48. This study's planned 12 months is below that.
Counting every sponsor, half of 309 studies reached it within 28 months; a quarter within 13 and three quarters within 48.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Inositol
Medical University of Vienna →